Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Health

V-Bio Ventures finalises Fund 2

Venture capital firm V-Bio Ventures has reached the final close of its second fund, with Vanden Avenue Commodities among the limited partners.


Mar 31, 2022

SoftBank spearheads $100m Neuron23 round

The neurological disease treatment developer took its funding to over $213m, completing a series C round led by SoftBank Vision Fund 2.

Mar 31, 2022

LetsGetChecked to buy Veritas Genetics

LetsGetChecked is moving into genomics with the acquisition of the genetic testing technology provider, allowing Lilly Ventures Asia and Jiangsu Simcere to exit.

Mar 31, 2022

Exits: March 31, 2022

A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

Mar 31, 2022

Deals: March 31, 2022

The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.

Mar 31, 2022

V-Bio Ventures completes $120m fundraising

VIB-backed venture capital firm V-Bio Ventures has reached the final close of its second fund and hired Shelley Margetson as managing partner.

Mar 31, 2022

Daily Deal Round Up: March 30, 2022

Alibaba helped AR glasses provider Nreal take its funding to $200m in the past year while SGE led a $60m series D round for online coder recruitment service HackerRank.

Mar 30, 2022

Daily Deal Round Up: March 29, 2022

DigitalBridge Ventures led wireless adoption software developer Celona's $60m series C round while Papaya is paying up to $200m for Rakuten-backed payment platform developer Azimo.

Mar 29, 2022

Exits: March 29, 2022

A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

Mar 29, 2022

Deals: March 29, 2022

The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.

Mar 29, 2022

AN2 Therapeutics prices $69m IPO

The Brii Biosciences-backed lung disease treatment developer priced an upsized offering in the middle of its range.

Mar 29, 2022

Celsius heats up with $83m

Amgen Ventures and existing backers GV, Heritage Provider Network and Alexandria Venture Investments helped the cancer and IBD drug developer secure fresh funding.

Mar 28, 2022
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here